Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 24:2022:6587165.
doi: 10.1155/2022/6587165. eCollection 2022.

Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study

Affiliations

Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study

Dennis Steenhuis et al. Cardiovasc Ther. .

Abstract

Background: Multiple studies and meta-analyses examined the role of traditional risk factors for cardiovascular events in statin treatment-naive patients. Nowadays, millions receive such therapy for the primary prevention of cardiovascular events (CVE).

Objective: CVEs still occur in patients on primary preventive statin therapy. Therefore, further risk stratification within these patients is urgently needed.

Methods: Using the unique linkage between biomedical data and prescription data from the PharmLines Initiative, we assessed the role of several risk factors used in cardiovascular risk models, using a time-dependent Cox PH model, in the occurrence of drug treatment of CVEs after initiation of statin therapy.

Results: Among 602 statin therapy starters, 11% received drug treatment for CVE within an average follow-up period of 832 days. After multivariable modelling, cholesterol levels and blood pressure at baseline were no longer associated, whereas self-reported diabetes and increasing age were highly associated with the outcome when on statin therapy (hazard ratio (HR): 3.01, 95% confidence interval (95% CI): 1.48-6.12 and 1.04; 95% CI: 1.01-1.07, respectively). Males, smokers, and nonadherent patients had increased risks (HR 1.6, 1.12, and 1.18, resp.), though not statistically significant.

Conclusion: Drug treatment for CVEs after statin initiation is increased in patients with diabetes type 2, in aged patients, males, smokers, and those with poor adherence, while there was no association with baseline cholesterol levels and blood pressure. These factors should be taken into account during the monitoring of statin therapy and may lead to changes in statin treatment or risk-related lifestyle factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Scheme of exclusion route. Abbreviations: CVE: cardiovascular event.
Figure 2
Figure 2
Time-dependent AUC scores on the test set of the regularized Cox model until 8 years after the index date. Abbreviations: AUC: area under curve; CI: confidence interval.

Similar articles

Cited by

References

    1. Stichting Pharmaceutische Kengetallen. 25 Miljoen minder aan cholesterolverlagers 2019. 2020. https://www.sfk.nl/publicaties/PW/2019/20ac-25-miljoen-minder-aan-choles... .
    1. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta- analysis of data from 170 000 participants in 26 randomised trials. The Lancet . 2010;376(9753):1670–1681. doi: 10.1016/S0140-6736(10)61350-5. - DOI - PMC - PubMed
    1. Taylor F., Ward K., Moore T. H., et al. Statins for the primary prevention of cardiovascular disease. The Cochrane database of systematic reviews . 2013;2013(5, article Cd004816) - PMC - PubMed
    1. Nederlandse Huisartsen Genootschap. Praktische Handleiding bij de NHG-Standaard CVRM (2019) Nederlands: Huisartsen Genootschap; 2019. Mei 2019 ed.
    1. Conroy R. M., Pyörälä K., Fitzgerald A. P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal . 2003;24(11):987–1003. doi: 10.1016/S0195-668X(03)00114-3. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources